Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of DUR 928 Administered Intramuscularly (IM) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Larsucosterol (Primary)
- Indications Acute kidney injury; Fatty liver
- Focus Adverse reactions; Pharmacokinetics
- Sponsors DURECT Corporation
- 06 Jan 2016 Status changed from recruiting to completed.
- 06 Jan 2016 Positive results published in a Durect Corporation Media Release
- 19 May 2015 New trial record